stockrowReplimune Group, Inc.
REPL- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
Follow REPL
Alert me
Replimune Group, Inc. (REPL) Free cash flow
Replimune Group, Inc.'s free cash flow for fiscal 2026 was −$284.6M, compared with −$198.9M in fiscal 2025. Over the twelve months to 30 September 2026 it was −$245.7M. Over the past ten years it has ranged from −$284.6M (fiscal 2026) to −$7.3M (fiscal 2017) — the current reading is the lowest in ten years. Free cash flow has fallen for 5 consecutive fiscal years. Replimune Group, Inc. ranks 556th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2026 | −$284.6M | — |
| FY2025 | −$198.9M | — |
| FY2024 | −$191.1M | — |
| FY2023 | −$130.3M | — |
| FY2022 | −$84.5M | — |
| FY2021 | −$63.8M | — |
| FY2020 | −$67.1M | — |
| FY2019 | −$28.0M | — |
| FY2018 | −$16.2M | — |
| FY2017 | −$7.3M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$47.7M | — |
| Jun 2026 | −$75.7M | — |
| Mar 2026 | −$56.2M | — |
| Dec 2025 | −$66.1M | — |
| 35 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $177.0M |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$112.3M |
| ZYME Zymeworks Inc. compare | −$112.8M |
| VIR Vir Biotechnology, Inc. compare | −$141.9M |
| IMNM Immunome, Inc. compare | −$238.7M |
| REPL Replimune Group, Inc. | −$245.7M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$314.5M |
| VERA Vera Therapeutics, Inc. compare | −$338.9M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$524.5M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)